InspireMD initiated with a Buy at Lake Street

Lake Street analyst Frank Takkinen initiated coverage of InspireMD (NSPR) with a Buy rating and $5 price target InspireMD’s CGuard carotid artery stent has been used over 60,000 times outside the U.S. and the company is approaching “its most important catalyst,” FDA approval of its CGuard stent in the first half of 2025, the analyst tells investors. The firm, which thinks CGuard approval and commercial launch will be catalysts, believes InspireMD can quickly build a $50M CGuard business and a $25M SwitchGuard business by 2028.